Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | CMA1 | P23946 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | SMPD2 | O60906 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ACP3 | P15309 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472186 | 0.89 | SIGMAR1 (0.35) | KDM4ESIGMAR1CMA1CA12CA2 | |
| SCHEMBL472204 | 0.86 | ALDH1A1 (0.36) | KDM4ESIGMAR1ALDH1A1THRBHPGD | |
| SCHEMBL472185 | 0.86 | SIGMAR1 (0.33) | KDM4ESIGMAR1CMA1CA12CA2 | |
| SCHEMBL874259 | 0.84 | ALDH1A1 (0.33) | KDM4ESIGMAR1SMPD2TDP1ACP3 | |
| SCHEMBL472191 | 0.83 | ALDH1A1 (0.38) | KDM4ESMPD2TDP1ACP3ALDH1A1 | |
| SCHEMBL22341535 | 0.82 | ACP3 (0.39) | ACP3 | |
| SCHEMBL874869 | 0.82 | ACP3 (0.39) | ACP3 | |
| SCHEMBL20162518 | 0.80 | KDM4E (0.38) | KDM4EMMP2MMP9MMP8MMP14 | |
| SCHEMBL781267 | 0.80 | KDM4E (0.38) | KDM4EMMP2MMP9MMP8MMP14 | |
| SCHEMBL12496458 | 0.78 | CTSG (0.39) | KDM4EMMP9SMPD2ACP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| EP-4023299-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana PLC (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| EP-3447061-B1 | PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHORAMIDATE DERIVATIVE OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-20190201432-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | CARDIFF UNIVERSITY (GB) | 2019-07-04 | — | — | US | disclosed |
| EP-3031812-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-08-01 | — | — | EP | disclosed |
| EP-3031812-A1 | CHEMICAL COMPOUNDS | NuCana BioMed Limited (GB) | 2016-06-15 | — | — | EP | disclosed |
| EP-2681227-B1 | PHOSPHORAMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NUCANA BIOMED LTD (GB) | 2016-02-10 | — | — | EP | disclosed |
| EP-2681227-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2 ' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana Biomed Limited (GB) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012117246-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2 ' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NUCANA BIOMED LIMITED (GB) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | KDM4E 3452/4885SIGMAR1 4218/4885CMA1 4640/4885 |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | KDM4E 3419/4885SIGMAR1 4228/4885CMA1 4637/4885 |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | KDM4E 3371/4885SIGMAR1 4212/4885CMA1 4664/4885 |
| US-20190201432-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | KDM4E 3292/4885SIGMAR1 4298/4885CMA1 4695/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | KDM4E 3294/4885SIGMAR1 4272/4885CMA1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.